• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

ZTI-01(注射用磷霉素)在中性粒细胞减少小鼠大腿感染模型中对大肠杆菌、肺炎克雷伯菌和铜绿假单胞菌的药代动力学和药效学

Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.

作者信息

Lepak Alexander J, Zhao Miao, VanScoy Brian, Taylor Daniel S, Ellis-Grosse Evelyn, Ambrose Paul G, Andes David R

机构信息

Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.

Department of Medical Microbiology and Immunology, University of Wisconsin, Madison, Wisconsin, USA.

出版信息

Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.00476-17. Print 2017 Jun.

DOI:10.1128/AAC.00476-17
PMID:28396549
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5444146/
Abstract

Fosfomycin is a broad-spectrum agent with activity against Gram-positive and Gram-negative bacteria, including drug-resistant strains, such as extended-spectrum-beta-lactamase (ESBL)-producing and carbapenem-resistant (CR) Gram-negative rods. In the present study, the pharmacokinetic/pharmacodynamic (PK/PD) activity of ZTI-01 (fosfomycin for injection) was evaluated in the neutropenic murine thigh infection model against 5 , 3 , and 2 strains, including a subset with ESBL and CR phenotypes. The pharmacokinetics of ZTI-01 were examined in mice after subcutaneous administration of 3.125, 12.5, 50, 200, 400, and 800 mg/kg of body weight. The half-life ranged from 0.51 to 1.1 h, area under the concentration-time curve (AUC) ranged from 1.4 to 87 mg · h/liter, and maximum concentrations ranged from 0.6 to 42.4 mg/liter. Dose fractionation demonstrated the AUC/MIC ratio to be the PK/PD index most closely linked to efficacy ( = 0.70). Net stasis and bactericidal activity were observed against all strains. Net stasis was observed at 24-h AUC/MIC ratio values of 24, 21, and 15 for , , and , respectively. For the group, stasis was noted at mean 24-h AUC/MIC ratio targets of 23 and 1-log kill at 83. Survival in mice infected with 145 was maximal at 24-h AUC/MIC ratio exposures of 9 to 43, which is comparable to the stasis exposures identified in the PK/PD studies. These results should prove useful for the design of clinical dosing regimens for ZTI-01 in the treatment of serious infections due to and .

摘要

磷霉素是一种广谱抗菌剂,对革兰氏阳性菌和革兰氏阴性菌均有活性,包括耐药菌株,如产超广谱β-内酰胺酶(ESBL)和耐碳青霉烯类(CR)的革兰氏阴性杆菌。在本研究中,在中性粒细胞减少的小鼠大腿感染模型中评估了ZTI-01(注射用磷霉素)对5株、3株和2株细菌的药代动力学/药效学(PK/PD)活性,其中包括具有ESBL和CR表型的子集。在小鼠皮下注射3.125、12.5、50、200、400和800mg/kg体重后,检测了ZTI-01的药代动力学。半衰期为0.51至1.1小时,浓度-时间曲线下面积(AUC)为1.4至87mg·小时/升,最大浓度为0.6至42.4mg/升。剂量分割显示AUC/MIC比值是与疗效最密切相关的PK/PD指数(r = 0.70)。对所有菌株均观察到净抑菌和杀菌活性。对于[具体菌株A]、[具体菌株B]和[具体菌株C],分别在24小时AUC/MIC比值为24、21和15时观察到净抑菌。对于[具体菌株D]组,在平均24小时AUC/MIC比值目标为23时观察到抑菌,在83时观察到1个对数级杀灭。感染[具体菌株E] 145的小鼠在24小时AUC/MIC比值暴露为9至43时存活率最高,这与PK/PD研究中确定的抑菌暴露相当。这些结果对于设计ZTI-01治疗由[具体菌株F]和[具体菌株G]引起的严重感染的临床给药方案应是有用的。

相似文献

1
Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.ZTI-01(注射用磷霉素)在中性粒细胞减少小鼠大腿感染模型中对大肠杆菌、肺炎克雷伯菌和铜绿假单胞菌的药代动力学和药效学
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.00476-17. Print 2017 Jun.
2
Pharmacodynamic Characterization of a Novel Odilorhabdin Antibiotic, NOSO-502, against Escherichia coli and Klebsiella pneumoniae in a Murine Thigh Infection Model.新型奥多利福菌素抗生素 NOSO-502 对小鼠大腿感染模型中大肠杆菌和肺炎克雷伯菌的药效学特征。
Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.01067-18. Print 2018 Sep.
3
Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model.依拉环素在小鼠大腿感染模型中对大肠杆菌的药效学靶点评估
Antimicrob Agents Chemother. 2017 Jun 27;61(7). doi: 10.1128/AAC.00250-17. Print 2017 Jul.
4
Pharmacokinetics and Pharmacodynamics of Fosfomycin and Its Activity against Extended-Spectrum-β-Lactamase-, Plasmid-Mediated AmpC-, and Carbapenemase-Producing Escherichia coli in a Murine Urinary Tract Infection Model.磷霉素的药代动力学和药效学及其对产超广谱β-内酰胺酶、质粒介导的 AmpC 和碳青霉烯酶的大肠埃希菌在小鼠尿路感染模型中的活性。
Antimicrob Agents Chemother. 2018 May 25;62(6). doi: 10.1128/AAC.02560-17. Print 2018 Jun.
5
In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus.在中性粒细胞减少小鼠大腿模型中,针对肺炎链球菌和金黄色葡萄球菌,对两种细菌拓扑异构酶抑制剂ACT - 387042和ACT - 292706进行体内药效学靶点研究。
Antimicrob Agents Chemother. 2016 May 23;60(6):3626-32. doi: 10.1128/AAC.00363-16. Print 2016 Jun.
6
In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model.在小鼠肺部感染模型中对达氟沙星针对金黄色葡萄球菌、肺炎链球菌和肺炎克雷伯菌的体内药效学靶点评估
Antimicrob Agents Chemother. 2016 Jul 22;60(8):4764-9. doi: 10.1128/AAC.00647-16. Print 2016 Aug.
7
Investigations on Pharmacokinetic/Pharmacodynamic Determinants of Fosfomycin in Murine Thigh and Kidney Infection Models.磷霉素在小鼠大腿和肾脏感染模型中的药代动力学/药效学决定因素研究。
Microb Drug Resist. 2023 Jan;29(1):18-27. doi: 10.1089/mdr.2022.0119. Epub 2022 Nov 8.
8
In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model.羊毛硫抗生素NAI-107在中性粒细胞减少小鼠大腿感染模型中的体内药代动力学和药效学
Antimicrob Agents Chemother. 2015 Feb;59(2):1258-64. doi: 10.1128/AAC.04444-14. Epub 2014 Dec 15.
9
Bioluminescent Monitoring of Therapeutic Efficacy and Pharmacodynamic Target Assessment of Antofloxacin against Escherichia coli in a Neutropenic Murine Thigh Infection Model.荧光素酶法监测安妥沙星对中性粒细胞减少症小鼠大腿感染模型中大肠杆菌的治疗效果和药效学靶标评估。
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01281-17. Print 2018 Jan.
10
Pharmacodynamics of imipenem in combination with β-lactamase inhibitor MK7655 in a murine thigh model.亚胺培南与β-内酰胺酶抑制剂MK7655联合用药在小鼠大腿模型中的药效学研究
Antimicrob Agents Chemother. 2015 Feb;59(2):790-5. doi: 10.1128/AAC.03706-14. Epub 2014 Nov 17.

引用本文的文献

1
Monitoring Plasma Concentrations of Intravenously Administered Fosfomycin to Prevent Drug-Related Adverse Events: A Retrospective Observational Study.监测静脉注射磷霉素的血药浓度以预防药物相关不良事件:一项回顾性观察研究。
Antibiotics (Basel). 2025 May 27;14(6):548. doi: 10.3390/antibiotics14060548.
2
Emerging Concepts for the Treatment of Biofilm-Associated Bone and Joint Infections with IV Fosfomycin: A Literature Review.静脉注射磷霉素治疗生物膜相关骨与关节感染的新观念:文献综述
Microorganisms. 2025 Apr 23;13(5):963. doi: 10.3390/microorganisms13050963.
3
Harnessing endogenous anti-glycan antibodies using a novel, bifunctional immunotherapy to treat gram-negative bacterial infections.利用一种新型双功能免疫疗法来利用内源性抗聚糖抗体治疗革兰氏阴性细菌感染。
J Immunol. 2025 Jul 1;214(7):1617-1629. doi: 10.1093/jimmun/vkaf055.
4
Determining an appropriate fosfomycin (ZTI-01) dosing regimen in pneumonia patients by utilizing minimal PBPK modeling and target attainment analysis.利用最小化生理药代动力学(PBPK)模型和达标分析确定肺炎患者合适的磷霉素(ZTI-01)给药方案。
Antimicrob Agents Chemother. 2025 Jun 4;69(6):e0186924. doi: 10.1128/aac.01869-24. Epub 2025 May 5.
5
Population pharmacokinetics of intravenous fosfomycin: dose optimization for critically ill patients with and without kidney replacement therapy.静脉注射磷霉素的群体药代动力学:接受和未接受肾脏替代治疗的重症患者的剂量优化
Antimicrob Agents Chemother. 2025 Jun 4;69(6):e0177924. doi: 10.1128/aac.01779-24. Epub 2025 May 5.
6
Carbapenem treatment options for metallo-beta-lactamase: drug screening and dose optimization of meropenem-based combinations against NDM- or IMP-producing .金属β-内酰胺酶的碳青霉烯治疗方案:针对产NDM或IMP菌株的基于美罗培南联合用药的药物筛选及剂量优化
Front Microbiol. 2025 Apr 15;16:1490372. doi: 10.3389/fmicb.2025.1490372. eCollection 2025.
7
Could a Reduced Dose of 8 g of Continuous Infusion Fosfomycin Be Considered as Effective as and Safer than a Standard 16 g Dose When Combined with High-Dose Daptomycin in the Treatment of Infections?当与大剂量达托霉素联合用于治疗感染时,持续输注8克磷霉素的减量剂量是否可被认为与标准的16克剂量一样有效且更安全?
Antibiotics (Basel). 2025 Feb 1;14(2):139. doi: 10.3390/antibiotics14020139.
8
PK/PD-Guided Strategies for Appropriate Antibiotic Use in the Era of Antimicrobial Resistance.抗菌药物耐药时代基于药代动力学/药效学指导的合理使用抗生素策略
Antibiotics (Basel). 2025 Jan 14;14(1):92. doi: 10.3390/antibiotics14010092.
9
Optimized fosfomycin regimens for treating carbapenem-resistant Acinetobacter baumannii in critically ill patients with varying degrees of renal function.优化的磷霉素方案治疗不同肾功能严重程度的危重症患者耐碳青霉烯鲍曼不动杆菌。
Clin Transl Sci. 2024 Oct;17(10):e70038. doi: 10.1111/cts.70038.
10
Assessing the Influence of Urine pH on the Efficacy of Ciprofloxacin and Fosfomycin in Immunocompetent and Immunocompromised Murine Models of and Infection in the Lower Urinary Tract.评估尿pH值对环丙沙星和磷霉素在下尿路大肠埃希菌和粪肠球菌感染的免疫健全和免疫受损小鼠模型中疗效的影响。
Antibiotics (Basel). 2024 Sep 1;13(9):827. doi: 10.3390/antibiotics13090827.

本文引用的文献

1
Notes from the Field: Pan-Resistant New Delhi Metallo-Beta-Lactamase-Producing Klebsiella pneumoniae - Washoe County, Nevada, 2016.实地记录:产泛耐药新德里金属β-内酰胺酶的肺炎克雷伯菌——内华达州瓦肖县,2016年
MMWR Morb Mortal Wkly Rep. 2017 Jan 13;66(1):33. doi: 10.15585/mmwr.mm6601a7.
2
Treatment of MDR-Gram negative infections in the 21st century: a never ending threat for clinicians.21世纪多重耐药革兰氏阴性菌感染的治疗:对临床医生来说是永无休止的威胁。
Curr Opin Pharmacol. 2015 Oct;24:30-7. doi: 10.1016/j.coph.2015.07.001. Epub 2015 Jul 24.
3
In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa.磷霉素对铜绿假单胞菌临床分离株的体外药效学
J Antimicrob Chemother. 2015 Nov;70(11):3042-50. doi: 10.1093/jac/dkv221. Epub 2015 Jul 24.
4
Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance.磷霉素的药效学:对抗菌药物耐药性临床应用的见解
Antimicrob Agents Chemother. 2015 Sep;59(9):5602-10. doi: 10.1128/AAC.00752-15. Epub 2015 Jun 29.
5
Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using an In Vitro Infection Model.使用体外感染模型探索磷霉素疗效的药代动力学-药效学关系
Antimicrob Agents Chemother. 2015 Dec;59(12):7170-7. doi: 10.1128/AAC.04955-14. Epub 2015 Jun 22.
6
Antifungal pharmacokinetics and pharmacodynamics.抗真菌药物的药代动力学与药效学
Cold Spring Harb Perspect Med. 2014 Nov 10;5(5):a019653. doi: 10.1101/cshperspect.a019653.
7
A new strategy to fight antimicrobial resistance: the revival of old antibiotics.对抗抗菌素耐药性的新策略:旧抗生素的复兴。
Front Microbiol. 2014 Oct 20;5:551. doi: 10.3389/fmicb.2014.00551. eCollection 2014.
8
What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review.磷霉素药代动力学在治疗危重症患者严重感染中的相关性如何?系统评价。
Int J Antimicrob Agents. 2013 Oct;42(4):289-93. doi: 10.1016/j.ijantimicag.2013.05.018. Epub 2013 Jul 20.
9
Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents.将疗效指标与抗感染药物的游离药物浓度相关联的重要性。
Clin Microbiol Rev. 2013 Apr;26(2):274-88. doi: 10.1128/CMR.00092-12.
10
The future of antibiotics and resistance.抗生素与耐药性的未来。
N Engl J Med. 2013 Jan 24;368(4):299-302. doi: 10.1056/NEJMp1215093.